First Trust Advisors LP Sells 103,504 Shares of BioNTech SE (NASDAQ:BNTX)

First Trust Advisors LP lowered its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 22.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 347,688 shares of the company's stock after selling 103,504 shares during the period. First Trust Advisors LP owned 0.15% of BioNTech worth $39,619,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Daiwa Securities Group Inc. boosted its stake in BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after purchasing an additional 128 shares during the period. Bank of New York Mellon Corp boosted its position in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after buying an additional 150 shares during the period. Midwest Professional Planners LTD. grew its holdings in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after buying an additional 222 shares in the last quarter. Perigon Wealth Management LLC increased its position in BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after acquiring an additional 224 shares during the period. Finally, Atomi Financial Group Inc. raised its stake in BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after acquiring an additional 229 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BNTX shares. Citigroup started coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target for the company. BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. HC Wainwright dropped their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Morgan Stanley decreased their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $143.44.

BioNTech Stock Down 15.4 %

BioNTech stock traded down $18.52 during mid-day trading on Friday, hitting $102.02. The company's stock had a trading volume of 6,438,309 shares, compared to its average volume of 899,284. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The firm's 50 day moving average is $101.72 and its 200 day moving average is $110.54. The company has a market cap of $24.48 billion, a PE ratio of -48.58 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.90 EPS. On average, analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.